As interest in therapeutic TIDES grows, regulatory agencies are increasingly requiring more rigorous characterization to ensure patient safety, drug efficacy, and quality. To meet these demands, ...
In 2014, Agilent Technologies announced that it would stop selling nuclear magnetic resonance systems. Agilent, which had acquired its NMR rival Varian in 2010, continued to fulfill existing orders, ...
This technique’s ability to highlight molecular structure and track reaction dynamics has garnered widespread recognition throughout academia and industry as a robust, nondestructive, noninvasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results